Eton Derma Labs paying $200,000 to settle FTC case involving Acne-Statin ad claims.
This article was originally published in The Rose Sheet
Executive Summary
ETON DERMA LABS TO PAY $200,000 IN ACNE STATIN SETTLEMENT WITH FTC involving charges by the Federal Trade Commission that ads claiming the Acne Statin kit is an effective treatment for severe or cystic acne are "deceptive" and not allowed under the OTC monograph for acne products. Under the proposed consent agreement, announced July 30, Eton Derma Labs and its principal, Atida Karr, will pay the civil penalty and refrain from using ads with the words "severe" or "cystic" acne. The firm also is prohibited from using photographs, videos or other depictions of individuals with cystic acne.